Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 305

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

ADP‐ribosyltransferases, an update on function and nomenclature

Open access
Lüscher, Bernhard, Ahel, Ivan, Altmeyer, Matthias, Ashworth, Alan, Bai, Peter, Chang, Paul, Cohen, Michael, Corda, Daniela, Dantzer, Françoise, Daugherty, Matthew D., Dawson, Ted M., Dawson, Valina L., Deindl, Sebastian, Fehr, Anthony R., Feijs, Karla L. H., Filippov, Dmitri V., Gagné, Jean‐Philippe, Grimaldi, Giovanna, Guettler, Sebastian, Hoch, Nicolas C., Hottiger, Michael O., Korn, Patricia, Kraus, W. Lee, Ladurner, Andreas, Lehtiö, Lari, Leung, Anthony K. L., Lord, Christopher J., Mangerich, Aswin, Matic, Ivan, Matthews, Jason, Moldovan, George‐Lucian, Moss, Joel, Natoli, Gioacchino, Nielsen, Michael L., Niepel, Mario, Nolte, Friedrich, Pascal, John, Paschal, Bryce M., Pawłowski, Krzysztof, Poirier, Guy G., Smith, Susan, Timinszky, Gyula, Wang, Zhao‐Qi, Yélamos, José, Yu, Xiaochun, Zaja, Roko, Ziegler, Mathias·2022·The FEBS Journal

Abstract

ADP‐ribosylation, a modification of proteins, nucleic acids, and metabolites, confers broad functions, including roles in stress responses elicited, for example, by DNA damage and viral infection and is involved in intra‐ and extracellular signaling, chromatin and transcriptional regulation, protein biosynthesis, and cell death. ADP‐ribosylation is catalyzed by ADP‐ribosyltransferases (ARTs), which transfer ADP‐ribose from NAD+ onto substrates. The modification, which occurs as mono‐ or poly‐ADP‐ribosylation, is reversible due to the action of different ADP‐ribosylhydrolases. Importantly, inhibitors of ARTs are approved or are being developed for clinical use. Moreover, ADP‐ribosylhydrolases are being assessed as therapeutic targets, foremost as antiviral drugs and for oncological indications. Due to the development of novel reagents and major technological advances that allow the study of ADP‐ribosylation in unprecedented detail, an increasing number of cellular processes and pathways are being identified that are regulated by ADP‐ribosylation. In addition, characterization of biochemical and structural aspects of the ARTs and their catalytic activities have expanded our understanding of this protein family. This increased knowledge requires that a common nomenclature be used to describe the relevant enzymes. Therefore, in this viewpoint, we propose an updated and broadly supported nomenclature for mammalian ARTs that will facilitate future discussions when addressing the biochemistry and biology of ADP‐ribosylation. This is combined with a brief description of the main functions of mammalian ARTs to illustrate the increasing diversity of mono‐ and poly‐ADP‐ribose mediated cellular processes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/febs.16142

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Cited by

Metadata

Authors
Lüscher, B., Ahel, I., Altmeyer, M., Ashworth, A., Bai, P., Chang, P., Cohen, M., Corda, D., Dantzer, F., Daugherty, M. D., Dawson, T. M., Dawson, V. L., Deindl, S., Fehr, A. R., Feijs, K. L. H., Filippov, D. V., Gagné, J., Grimaldi, G., Guettler, S., Hoch, N. C., Hottiger, M. O., Korn, P., Kraus, W. L., Ladurner, A., Lehtiö, L., Leung, A. K. L., Lord, C. J., Mangerich, A., Matic, I., Matthews, J., Moldovan, G., Moss, J., Natoli, G., Nielsen, M. L., Niepel, M., Nolte, F., Pascal, J., Paschal, B. M., Pawłowski, K., Poirier, G. G., Smith, S., Timinszky, G., Wang, Z., Yélamos, J., Yu, X., Zaja, R., & Ziegler, M.
Venue
The FEBS Journal
Publisher
Wiley
Published
2021-09-13
Volume
289
Issue
23
Pages
7399-7410
ISSN
  • 1742-464X (ISSN-L)
  • 1742-4658
OpenAlex
W3183970717
Cited by
305
References
69
FWCI
13.22
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.